Full text is available at the source.
Abstract
Icaritin (ICT) treatment significantly improved liver health in a mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD).
- ICT reduced liver fat accumulation and improved lipid profiles in mice fed a high-fat diet.
- The treatment reversed the downregulation of genes associated with cholesterol transport.
- ICT altered the expression profiles of key metabolic pathways, particularly in glycogen and lipid metabolism.
- In vitro studies showed that ICT also reversed the suppression of the GSTA1 gene in liver cells.
- A direct interaction between ICT and the GSTA1 protein was confirmed through molecular docking and thermal shift assays.
- Knocking down GSTA1 in liver cells negated the protective effects of ICT, indicating its crucial role in the treatment.
Simplified